Drugs / SynKIR-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05568680 | Mar 2023 → Dec 2027 expected | cholangiocarcinoma, malignant mesothelioma, ovarian cancer | Verismo Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SynKIR-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05568680 ↗ |
| Modality | Cell therapy | “Autologous T cells Transduced with Mesothelin KIR-CAR” NCT05568680 ↗ |
| Route | Intravenous | “single intravenous (IV) dose” NCT05568680 ↗ |